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Abstract: Several poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors are now in
clinical use for tumours with defects in BReast CAncer genes BRCA1 or BRCA2 that result in
deficient homologous recombination repair (HRR). Use of olaparib, niraparib or rucaparib for the
treatment of high-grade serous ovarian cancer, including in the maintenance setting, has extended
both progression free and overall survival for women with this malignancy. While different PARP
inhibitors (PARPis) are mechanistically similar, differences are apparent in their chemical structures,
toxicity profiles, PARP trapping abilities and polypharmacological landscapes. We have treated
ovarian cancer cell line models of known BRCA status, including the paired cell lines PEO1 and PEO4,
and UWB1.289 and UWB1.289+BRCA1, with five PARPis (olaparib, niraparib, rucaparib, talazoparib
and veliparib) and observed differences between PARPis in both cell viability and cell survival. A cell
line model of acquired resistance to veliparib showed increased resistance to the other four PARPis
tested, suggesting that acquired resistance to one PARPi may not be able to be rescued by another.
Lastly, as a proof of principle, HRR proficient ovarian cancer cells were sensitised to PARPis by
depletion of BRCA1. In the future, guidelines will need to emerge to assist clinicians in matching
specific PARPis to specific patients and tumours.
Keywords: BRCA1; BRCA2; homologous recombination repair; PARP inhibitor; olaparib; rucaparib;
niraparib; talazoparib; veliparib
1. Introduction
The advent of pharmacological inhibitors of the DNA repair enzyme poly (adenosine
diphosphate-ribose) polymerase (PARP) has heralded major therapeutic advances for
malignancies that have defects in components of homologous recombination repair (HRR)
pathways [1–3]. The focus of PARP inhibitors (PARPis) to date has been on BRCA1 and
BRCA2 mutated tumours, with clinical benefits seen in patients with mutations in these
DNA repair genes such as ovarian [4], breast [5], prostate [6] and pancreatic cancers [7].
BRCA1 methylated tumours are also sensitive to PARP inhibition [8], as are tumours with
mutations in other genes that function in repair of double strand breaks (DSBs), including
RAD51C, RAD51D, ATM and PALB2, where tumours are described as having a “BRCAness”
phenotype [8–10]. With this broadening concept of BRCAness, other malignancies are
being investigated to assess sensitivity to PARP inhibitors, including colorectal, upper
gastrointestinal and acute myeloid leukemia [1,11–13].
PARP family members function in a number of cellular processes including the regu-
lation of gene transcription, chromatin remodelling and DNA repair [14,15]. PARPs bind
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to DNA at sites of single strand breaks (SSBs) undergoing base excision repair (BER) where
they function to recruit DNA repair machinery. When the replication fork comes across a
SSB, DSBs are generated that then need to undergo HRR [16,17]. BER is the default repair
pathway for cells with defects in HRR, the preferred pathway for repair of DSBs, such
as occurs in the presence of BRCA mutations. By inhibiting PARP function in cells with
deficient HRR, cells lose their ability to choose the default BER pathway to repair DNA
damage, creating synthetic lethality that leads to cell death [18–20].
PARP1, PARP2, PARP3, PARP4 (also known as Vault PARP) and tankyrases 1 and 2
(PARP5a and PARP5b) are amongst the most studied members of the PARP family [2,15].
Catalytic activation of PARP1 synthesises poly (ADP-ribose), PAR, from the substrate
nicotinamide adenine dinucleotide (NAD+) in a process known as PARylation. While
PARP1 is reported to conduct more than 90% of PARylation associated with DNA damage,
PARPs 2, 3, 4, 5a and 5b also demonstrate PARylation activity [21,22]. Inhibition of these
PARP enzymes and in turn the PARylation process has proven to be a major advancement
in the treatment of HRR deficient tumours [1–3,23,24].
Olaparib (Lynparza®) was the first PARPi endorsed by the Food and Drug Administra-
tion (FDA) for the treatment of advanced germline BRCA-mutated ovarian cancer in 2014,
followed by rucaparib (Rubraca®) for use to treat the same indication in 2016 [18,25–27].
Olaparib and rucaparib were sanctioned in 2018 for use as maintenance therapy for women
with ovarian cancer following surgery. Niraparib (Zejula®) was endorsed in 2020 by the
FDA as maintenance for advanced epithelial ovarian, fallopian tube or primary peritoneal
cancer where patients have had complete or partial response to first-line platinum-based
chemotherapy [28]. Talazoparib (Talzenna®) became licensed by the FDA in 2018 for the
treatment of BRCA-mutated HER2-negative breast cancers [29]. Veliparib (ABT-888) is
one of a number of PARPis that have not been endorsed to date for mainstream clinical
use. Each of these PARPis has a unique structure and different binding affinities for PARP
family members [25,30]. Furthermore, these PARPis display differential PARP trapping
potencies, where the PARP complex locks onto or becomes trapped on DNA at the site of
breakage, thus preventing binding of other DNA repair factors [17,31]. The PARP trapping
potency of these five PARPis from highest to lowest is talazoparib, niraparib, rucaparib,
olaparib, then veliparib [24]. While amongst the most efficacious molecular target drugs
of recent times, tumours can display innate or acquired resistance to PARPis. The rea-
sons for this include innate HRR proficiency, reversion of BRCA mutations or mutations
in other HRR-related genes such as PALB2 or RAD51C, loss of BRCA1 methylation that
re-establishes HRR proficiency, the increase in expression of drug efflux pumps such as the
MDR1 (p-glycoprotein) gene, aberrant replication fork protection and down-regulation of
PARP proteins themselves, possibly as a result of PARP trapping [32,33].
Here, we have focused on ovarian cancer, where over 50% of the most common sub-
type high-grade serous ovarian cancer (HGSOC) have defects in genes that function in
HRR [32]. We use models of BRCA wild-type and mutant ovarian cancer to investigate the
efficacy of five PARPis—olaparib, rucaparib, niraparib, talazoparib and veliparib—on cell
viability and cell survival. Further, we have investigated whether acquired PARP resistance
to veliparib can be overcome by use of other PARPis. Lastly, we manipulated HRR by
down-regulating BRCA1 in BRCA1 wild-type cells, including in OVCAR-3 cells known
to harbor a CCNE1 amplification and be HRR proficient, to determine whether we could
sensitise cells to PARP inhibitors.
2. Results
2.1. PARPis Display Differential Efficacy on Cell Viability in BRCA Wild-Type and Mutant
Ovarian Cancer Cell Line Pairs
LC50 levels of five PARPis (olaparib, niraparib, rucaparib, talazoparib and veli-
parib) in PEO1 and PEO4 (Figure 1A), as well as UWB1.289 and UWB1.289+BRCA1 cells
(Figure 1B), were determined from dose curves of each drug and endpoint MTS assay
(Figures S1 and S2). Doses and serial dilutions used for each PARPi in different cell lines
for all experiments are summarised in Table S1. BRCA2 mutant PEO1 cells were responsive
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to olaparib, niraparib and talazoparib over the dose curve compared with wild-type (WT)
PEO4 cells, but not to rucaparib and veliparib in the context of cell viability (Figure S1).
Veliparib displayed the highest of all LC50s at 47.59 µM in PEO1 cells and 28.13 µM in
PEO4, suggesting that the PEO1/PEO4 cell line pair are highly resistant to this PARPi. Both
WT PEO4 and the mutant PEO1 cell pair were highly sensitive to talazoparib (LC50s of
0.0557 and 0.0729 µM, respectively), suggesting that this sensitivity was independent of
BRCA2 status (Table 1).
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 3 of 14 
 
 
LC50 levels of five PARPis (olaparib, niraparib, rucaparib, talazoparib and veliparib) 
in PEO1 and PEO4 (Figure 1A), as well as UWB1.289 and UWB1.289+BRCA1 cells (Figure 
1B), were determined from dose curves of each drug and endpoint MTS assay (Figures S1 
and S2). Doses and serial dilutions used for each PARPi in different cell lines for all exper-
iments are summarised in Table S1. BRCA2 mutant PEO1 cells were responsive to 
olaparib, niraparib and talazoparib over the dose curve compared with wild-type (WT) 
PEO4 cells, but not to rucaparib and veliparib in the context of cell viability (Figure S1). 
Veliparib displayed the highest of all LC50s at 47.59 µM in PEO1 cells and 28.13 µM in 
PEO4, suggesting that the PEO1/PEO4 cell line pair are highly resistant to this PARPi. 
Both WT PEO4 and the mutant PEO1 cell pair were highly sensitive to talazoparib (LC50s 
of 0.0557 and 0.0729 µM, respectively), suggesting that this sensitivity was independent 
of  status (Table 1). 
 
Figure 1. LC50 calculated from cell viability (MTS assay) data for each of five PARPis (talazoparib, rucaparib, olaparib, 
niraparib and veliparib) in (A) PEO1 and PEO4; (B) UWB1.289 and UWB1.289+BRCA1. LC50 calculated from cell survival 
(clonogenic assay) data for the identical five PARPis in (C) PEO1 and PEO4; (D) UWB1.289 and UWB1.289+BRCA1. 
Table 1. LC50 comparisons (cell proliferation; MTS) for PARPis in BRCA1/2–WT paired HGSOC 
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PARPi 
 PEO1 PEO4  
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rucaparib 2.6370 3.2140 1.22 
olaparib 2.3560 2.5710 1.09 
talazoparib 0.0729 0.0557 0.76 
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Figure 1. LC50 calculated from cell viability (MTS a say) each of five PARPis (talazoparib, rucaparib, olaparib,
niraparib and vel parib) in (A) PEO1 and PEO4; (B) U B d UWB1.289+BRCA1. LC50 cal ulated from cell survival
(clo ogenic assay) data for the identical five PARPis i ) EO1 and PEO4; (D) UWB1.289 and UWB1.289+BRCA1.
BRCA1 mutant UWB1.289 cells were more responsive to all five PARPis tested based
on LC50 data, compared to the paired cell line UWB1.289+BRCA1 (Table 1). Similar to
the PEO paired cell lines, the UWB1.289 paired lines displayed the greatest sensitivity
to talazoparib (Table 1). Niraparib showed the greatest discrimination i both cell line
pairs based on the largest fold change in LC50 between mutant and WT cells, followed
by rucaparib (Table 1). Further, greater fold changes based on LC50 data in response to
all PARPis were seen in the BRCA1 mutant and WT pair UWB1.289 compared with the
BRCA2 mutant and WT pair PEO1 and PEO4 (Table 1). This suggests that different BRCA
mutations may respond differently to a range of PARPis.
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Table 1. LC50 comparisons (cell proliferation; MTS) for PARP is in BRCA1/2–WT paired HGSOC cell
lines and a parental–veliparib resistant endometrioid ovarian cancer cell line.




niraparib 1.9300 5.0640 2.62
rucaparib 2.6370 3.2140 1.22
olaparib 2.3560 2.5710 1.09
talazoparib 0.0729 0.0557 0.76
veliparib 47.5900 28.1300 0.59
UWB1.289 vs. UWB1.289 + BRCA1
UWB1.289 UWB1.289 + BRCA1
niraparib 0.6936 2.4620 3.55
rucaparib 2.2560 7.9120 3.51
veliparib 4.8490 15.7200 3.24
olaparib 0.1679 0.4920 2.93
talazoparib 0.0025 0.0062 2.52
A2780 vs. A2780VeliR
A2780 A2780VeliR
talazoparib 0.0024 0.0347 14.41
rucaparib 1.1440 6.3480 5.55
veliparib 16.62 57.49 3.46
niraparib 0.2934 0.8718 2.97
olaparib 0.8735 2.2230 2.54
ˆ fold change is displayed in descending order.
2.2. PARPis Display Differential Efficacy on Cell Survival in BRCA Wild-Type and Mutant
Ovarian Cancer Cell Line Pairs
LC50 doses calculated using cell survival data from clonogenic assays of each PARPi
in BRCA WT and mutant pairs were determined (Table 2, Figure 1C,D). As expected,
greater sensitivity to all PARPis was seen in the BRCA mutant cell line of each pair (PEO1
and PEO4, Figure S3; UWB1.289 and UWB1.289+BRCA1, Figure S4) in the context of cell
survival. As for cell viability, based on LC50 doses, the greatest sensitivity was observed for
talazoparib in all cell lines (Table 2). Again, as for cell viability, differences in cell survival
post treatment with different PARPis were seen in both of the cell line pairs tested. Veliparib
showed the greatest fold change in the UWB1.289 pair, with a 47.36-fold difference in LC50
between the mutant and WT cell lines (Table 2). Curiously, veliparib showed the least fold
difference in LC50 values between the mutant and WT PEO pair, with rucaparib showing
the largest fold change at 12.78 (Table 2). Overall, greater fold differences in all PARPis
were observed in the UWB1.289 pair compared to the PEO pair (Table 2). This observation
was also true for cell viability (Table 1).
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Table 2. LC50 comparisons (cell survival; clonogenic assay) for PARP is in BRCA1/2–WT paired
HGSOC cell lines and a parental–veliparib resistant endometrioid ovarian cancer cell line.




rucaparib 0.0417 0.5332 12.78
niraparib 0.2168 0.9263 4.27
olaparib 0.1405 0.4935 3.51
talazoparib 0.00008 0.00017 2.23
veliparib 4.445 8.2154 1.85
UWB1.289 vs. UWB1.289 + BRCA1
UWB1.289 UWB1.289 + BRCA1
veliparib 0.1745 8.2640 47.36
rucaparib 0.0066 0.2592 39.30
olaparib 0.0091 0.2446 26.77
niraparib 0.0178 0.1889 10.63
talazoparib 0.00005 0.00026 4.86
A2780 vs. A2780VeliR
A2780 A2780VeliR
olaparib 0.0052 0.1206 23.03
rucaparib 0.0071 0.0915 12.97
veliparib 0.5395 4.7707 8.84
talazoparib 0.00003 0.0001 2.99
niraparib 0.0194 0.0484 2.49
ˆ fold change is displayed in descending order.
2.3. Veliparib Resistant A2780 Cells Retain Resistance to Other PARP Inhibitors
Given that different PARPis target PARP family members with varying efficiency, as
well as show differences in their PARP trapping potency, we sought to determine whether
olaparib, niraparib, talazoparib or rucaparib could rescue acquired resistance to veliparib.
The A2780veliR cell line was developed in-house by the addition of increasing doses of
ABT-888 and based on LC50 dose calculated from MTS assay was found to be 3.46-fold
more resistant to veliparib than parental A2780 cells (Table 1, Figure 2A and Figure S5).
Furthermore, based on LC50 doses calculated from cell survival data, A2780veliR cells
were 8.84-fold more resistant to veliparib than A2780 (Table 2, Figure 2B and Figure S6).
A2780veliR cells were between 2.54- to 14.41-fold more resistant to the other PARPis tested
than parental A2780 cells based on LC50 doses calculated from MTS data (Table 1, Figure
2A and Figure S5). Furthermore, LC50 levels calculated from clonogenic assays showed
that A2780veliR cells were between 2.49- to 23.03-fold more resistant to the other PARPis
tested (Table 2, Figure 2A and Figure S6). These data support the conclusion that acquired
veliparib resistance in vitro also leads to greater resistance to other PARPis. It therefore
seems unlikely that PARPis will be able to rescue acquired resistance to a specific PARPi, at
least in the case of resistance to veliparib.
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2.4. Down-Regulation of BRCA1 in BRCA1 Wild-Type Ovarian Cancer Cell Lines Sensitises Cells
to PARPis
Next, we sought to determine whether we could sensitise ovarian cancer cells to
PARP inhibition by down-regulation of a key component of HR, specifically BRCA1. We
chose two BRCA1 WT cell lines for this purpose, s ecifically OVCAR-3 with a known
CCNE1 amplification frequently associated with HR proficiency [34], and A2780 that has
been speculated to harbor a defect in DNA repair [35]. BRCA1 was down-regulated using
two independent siRNAs. We achieved between 56 and 62% BRCA1 down-regulation in
OVCAR-3 cells and 40–53% down-regulation in A2780 cells (Figure S7). Down-regulation
of BRCA1 alone in both cell lines decreased cell viability, by 12–33% in A2780 cells and
56–67% in OVCAR-3 cells (Figure 3). The large decrease in cell viability for OVCAR-3 cells
upon down-regulation of BRCA1 is likely due to the presence of a CCNE1 amplification,
previously reported as mutually exclusive events [36]. Down-regulation of BRCA1 in A2780
cells (Figure 3B and Figure S8) and OVCAR-3 cells (Figure 3D and Figure S9) lowered the
LC50 dose for all five PARPis, indicating that loss of BRCA1 in these cell lines sensitised
them to PARP inhibitors (Table 3).
2.5. Down-Regulation of BRCA1 in BRCA1 Wild-Type Ovarian Cancer Cell Lines Decreases
Cell Survival
We then sought to determine the effect of down-regulation of BRCA1 on cell survival
in A2780 and HR proficient OVCAR-3 cells. In both cases, down-regulation of BRCA1
caused a decrease in plating efficiency, with a greater decrease seen in OVCAR-3 cells
(Figure 4C) than A2780 cells (Figure 4A), indicating a significant basal effect on cell survival
of down-regulating BRCA1 in these cell line models. Dose curves of cell lines treated with
PARPis did not show a significant difference between cells treated with the non-silencing
control or either of two BRCA1 siRNAs (Figures S10 and S11). This is possibly due to the
fact that down-regulation of BRCA1 alone in these cells had a large effect on cell survival
and any additional effects of PARP inhibition were difficult to detect. With this in mind,
small differences in LC50 dose comparing the non-silencing control to cell lines in which
BRCA1 was down-regulated were observed for most PARPis in both cell line models
(Figure 4B,D, Table 3).
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of BRCA1 by two distinct siRNAs (#13 and #14) in (A) A2780 cells and (C) OVCAR-3 cells decreased cell viability measured
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l . LC50 comparisons (cell survival; clonogenic assays) for PARPis in cell lines with down-
regulated BRCA1.
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A2780 BRCA1 KD (cell viability)
olaparib 1.2330 0.1994 (6.18) 0.3539 (3.48)
rucaparib 0.8272 0.1886 (4.39) 0.3320 (2.49)
t lazoparib 0.0009 0.0003 (3.32) 0.0004 (2.32)
veliparib 16.9900 5.3730 (3.16) 8.0910 (2.10)
niraparib 0.4010 0.1910 (2.10) 0.1927 (2.08)
OVCAR-3 BRCA1 KD (cell viability)
talazoparib 0.0058 0.0006 (10.24) 0.0005 (11.81)
rucaparib 2.4500 0.1345 (18.22) 0.2293 (10.68)
niraparib 3.6650 0.4730 (7.75) 0.3468 (10.57)
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Table 3. Cont.
LC50 (µM)
AS BRCA1 si#13 (foldchange)
BRCA1 si#14 (fold
change ˆ)
olaparib 2.9110 0.4229 (6.88) 0.4687 (6.21)
veliparib 20.5600 3.2850 (6.26) 3.6540 (5.63)
A2780 BRCA1 KD (cell survival)
olaparib 0.0275 0.0075 (3.67) 0.0110 (2.50)
niraparib 0.0471 0.0204 (2.30) 0.0311 (1.51)
veliparib 1.1726 0.5215 (2.25) 0.8487 (1.38)
talazoparib 0.0006 0.0003 (2.10) 0.0004 (1.26)
rucaparib 0.0283 0.0119 (2.38) 0.0229 (1.24)
OVCAR-3 BRCA1 KD (cell survival)
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Figure 4. Down-regulation of BRCA1 decreased basal cell survival, and in some cases, sensitised cells to PARP inhibition.
Down-regulation of BRCA1 by two distinct siRNAs (#13 and #14) in (A) A2780 cells and (C) OVCAR-3 cells decreased
plating efficiency (N = 4; AS, AllStars control siRNA). LC50 data calculated from cell survival (clonogenic assay) for each of
the five PARPis (niraparib, olaparib, rucaparib, talazoparib and veliparib) after BRCA1 down-regulation in (B) A2780 cells
and (D) OVCAR-3 cells. * p < 0.05, ** p < 0.01.
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3. Discussion
The fundamental premise of targeting the cell’s DNA repair machinery has seen the
development and rapid uptake of PARPis in the clinic. Specific improvements have been
seen in both progression free and overall survival for women with HGSOC treated with
a PARPi [37–41]. Still, currently there is no clear rationale regarding which PARPi to use,
for which ovarian cancer patients beyond FDA endorsement of olaparib, rucaparib or
niraparib when a mutation is present in BRCA1 or BRCA2 after first-line platinum-based
chemotherapy or as maintenance therapy [30,42]. We show clear differences in response
and sensitivity to different PARPis in our cell line models with known BRCA mutation
status. Based on LC50 doses calculated from cell viability data, BRCA2 mutant PEO1 cells
were actually less sensitive to talazoparib and veliparib than their mutation reversion
counterpart cell line, PEO4. In contrast, UWB1.289 cells lacking BRCA1 were more sensitive
to all five PARPis tested, with larger fold differences in LC50 doses observed between this
cell line and its WT BRCA1 partner line compared with the PEO1/PEO4 pair for all PARPis
analysed. This larger fold difference in LC50 dose for the UWB1.289 pair compared to the
PEO1/PEO4 pair was also observed for cell survival calculated from clonogenic assays for
all PARPis analysed.
There are a number of possible explanations for these observations. It is possible
that there are inherent differences in response to PARPis based on whether tumours
have a BRCA1 or BRCA2 mutation. To date, few studies have explored this possibility,
although differences in response to PARPis in prostate cancer have been reported based on
whether the tumour was BRCA1 or BRCA2 mutated [43]. While PARPis are mechanistically
similar in that they all interact with the substrate NAD+ to inhibit PARylation and so
DNA repair, they also have a number of differences. PARPis have different chemical
structures and also differ in their ability to trap PARP1 on DNA, with talazoparib having
the strongest PARP trapping function, followed by niraparib, rucaparib, olaparib and lastly
veliparib [17,24]. This is consistent with our data that indicate talazoparib is the most
cytotoxic of the PARPis tested and veliparib the least. Polypharmacology has been reported
for PARP inhibitors. For example, niraparib and rucaparib have also been found to inhibit
some kinases including DYRK15, CDK16 and PIM3 that may be therapeutically useful if
these kinases are aberrantly expressed in specific tumours [25,44]. We cannot exclude the
possibility that aberrant regulation of certain members of the kinome in cell line models
used in this study may have affected the response to specific PARPis independently of
BRCA status.
While the mechanism of acquired resistance to veliparib is currently unknown in
our A2780veliR cells developed in-house from the A2780 parental cell line, we sought to
investigate whether this resistance could be overcome by treatment with an alternative
PARPi. The rationale for this strategy was based in the knowledge that different PARPis
have been shown to display differential affinity for PARP family members, as well as
different PARP trapping abilities [17,24,25,30,31]. Our data show that increased resistance
to veliparib was not able to be overcome by treatment with any of olaparib, niraparib,
rucaparib or talazoparib. In fact, increased resistance to veliparib led to increased resistance
to all the other PARPis tested and would suggest that employing alternative PARPis would
not be a successful clinical strategy to overcome acquired resistance to a PARPi. Testing
of cell lines with developed resistance to other PARPis would need to be undertaken to
further explore this phenomenon. Current approaches to overcoming PARPi resistance
include focus on the use of inhibitors of other participants in the DNA damage repair
response such as the cell cycle checkpoint regulators ATR, WEE1 and CHK1/2 [45–48].
Lastly, given the success of PARPis for women with HR deficient ovarian cancer, there
is a strong need to expand these benefits to women whose tumours are HR proficient. With
this in mind, in order to drive cells towards an HR deficient phenotype, we conducted a
proof-of-principle experiment where we down-regulated BRCA1 in HR proficient OVCAR-
3 cells, as well as in the A2780 cell line that is BRCA WT but has recently been suggested to
have defective DNA repair [35]. We then treated cells with all five PARPis. OVCAR-3 cells
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have an amplification of CCNE1 that has been reported as a mutually exclusive event to
defective HR [36]. In spite of the combination of CCNE1 amplification and loss of BRCA1
likely leading to synthetic lethality that would explain the large decrease in basal cell
viability in OVCAR-3 cells upon depletion of BRCA1, we did observe increased sensitivity
to all PARPis in BRCA1 down-regulated cells based on LC50 doses. This was not seen
in cell survival assays, likely due to the effects of synthetic lethality. In A2780 cell lines
that may already have defective DNA repair, increases in sensitivity to PARP inhibition
was observed following down-regulation of BRCA1 in both cell viability and cell survival
assays. This observation warrants broader exploration and suggests that responses to
PARPis may be amenable to further improvement by targeting of key participants in HRR,
even in cells that may already suffer impaired levels of DNA repair.
With multiple PARPis available now for clinical use, and likely additional ones in
development that will be endorsed for future use, stronger guidance will be required as
to which PARPi to choose for a specific patient, considering factors such as tumour type,
stage of disease, the involvement of HRR genes possibly down to the level of specific
mutations, as well as off-target effects of different PARPis that may be efficacious. The
routine incorporation of organoids generated from primary tumours or PDx models into
the clinical management of patients would assist in streamlining the choice of PARPi that
would best suit particular cases [49,50]. Pharmacological targeting of components of HRR
in HR proficient tumours may increase the cohort of patients who currently experience the
benefits of PARPi therapy beyond those whose tumours harbor defects in HRR pathways.
4. Materials and Methods
4.1. Cell Lines
The human HGSOC cell lines UWB1.289, UWB1.289+BRCA1 [51] and OVCAR-3 [52]
were purchased from the American Type Culture Collection (ATCC, Virginia, USA; re-
spectively, cat. #CRL-2945, #CRL-2946 and #HTB-161), while PEO1 and PEO4 were gifts
originating from Dr Simon Langdon [53]. UWB1.289 (University of Washington-BRCA1-
family 289) was derived from a recurrent human papillary serous ovarian cancer that
contained the c.2594delC germline mutation in exon 11 of BRCA1, resulting in a premature
STOP at codon 845 and a BRAC1-null phenotype. The corresponding WT BRCA1 allele was
also lost. UWB1.289+BRCA1 cells were created following stable transfection of WT BRCA1.
These paired cell lines also have a mutation in TP53, specifically c.625delAG and loss of
the TP53 WT allele. PEO1 and PEO4 cells were derived from peritoneal ascites of the same
patient who had a poorly differentiated serous adenocarcinoma. PEO1 cells were collected
after the patient was treated with cisplatin, 5-fluorouracil and chlorambucil. PEO4 cells
were collected after the patient demonstrated resistance to these drugs. PEO1 cells have the
BRCA2 mutation c.5193C>G, and PEO4 cells have a second mutation in BRCA2, c.5193C>T,
that restores WT BRCA2 [54,55]. This cell line pair also has a mutation in TP53, c.731G>A.
The endometroid ovarian cancer cell line A2780 was sourced from Sigma-Aldrich Pty. Ltd.
(cat. #93112591, Sydney, NSW, Australia) [35,52]. Clear defects in components of HRR
have not been identified in A2780 cells, although they have recently been reported to have
low levels of the repair factor RAD50 compared with their counterpart cisplatin resistant
line A2780cisR, suggesting they may harbour deficiencies in HRR [35]. Further, A2780
cells have previously been reported to exhibit sensitivity to a PARP inhibitor [56]. The
A2780veliR cell line is resistant to the PARPi veliparib (ABT-888, cat. #ALX-270-444-M005,
Sapphire Biosciences, Waterloo, NSW, Australia) and was developed in our laboratory from
the parental A2780 cell line by exposure to gradual increasing concentrations of ABT-888
(10–140 µM) over a 31-week period. Cells were then grown for 6 weeks veliparib free to
wash out any remaining drug.
All cell lines were grown in RPMI 1640 (cat. #42402016, Thermo Fisher Scientific,
Mulgrave, VIC, Australia) supplemented with 10% FBS (AusGeneX, Molendinar, QLD,
Australia), with the exception of the UWB1.289 and UWB1.289 + BRCA1 cell lines which
were maintained in 50% RPMI 1640 (HyClone #SH30027, GE Healthcare Life Sciences), 50%
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MEGM (Clonetics™ MEBM supplemented with SingleQuot additives cat. #CC-3150 from
LONZA, Walkersville, MD, USA), supplemented with 3% FBS at 37 ◦C in a humidified 5%
CO2 atmosphere.
Cell line authentication was performed by the Australian Genome Research Facility
(AGRF) Melbourne, Australia, by short tandem repeat (STR) profiling using the GenePrint-
10 System which co-amplifies ten loci, including the ASN-0002 loci (TH01, TPOX, vWA,
Amelogenin, CSF1PO, D16S539, D7S820, D13S317 and D5S818) as well as D21S11. All cell
lines tested negative for mycoplasma with the MycoAlertTM Mycoplasma Detection Kit
(cat. #LT07-318, LONZA, Walkersville, MD, USA).
4.2. BRCA1 Down-Regulation, RNA Extraction and qRT-PCR
Cells were seeded into 6-well plates (600,000/well for A2780; 1,000,000/well for OVCAR-
3) for 24 h followed by transfection with 20 nM BRCA1 siRNA #13 (cat. #SI02654575, Qiagen
(cat. #301707), Chadstone, VIC, Australia), BRCA1 siRNA #14 (cat. #SI02664361, Qiagen)
or a non-silencing negative control (Allstars, Qiagen) using HiPerfect transfection reagent
(Qiagen). After 18 h, siRNA transfected cells were re-seeded for MTS or clonogenic
assays. RNA was extracted 48 h post transfection using the RNeasy Mini kit (cat. #74106,
Qiagen) and 500 ng converted to cDNA using the SuperScript™ IV First-Strand Synthesis
System (SSIV, cat. #18091200, Thermo Fisher Scientific Australia Pty. Ltd., Scoresby, VIC,
Australia). Quantitative real-time PCR (qRT-PCR) was performed using the TaqMan Fast
Advanced Master Mix Kit (cat. #444557, Thermo Fisher Scientific) with Taqman assays
BRCA1 (cat. #Hs01556193_m1, Thermo Fisher Scientific) and hydroxymethylbilane synthase
(HMBS) endogenous control (cat. #97639748, Integrated DNA Technologies, Baulkham
Hills, NSW, Australia) on the QuantStudio 12K Flex Real-Time PCR System (Thermo Fisher
Scientific). Each experiment was performed in triplicate and repeated at least three times,
with data reported as the mean ± S.E.M.
4.3. Cell Viability Assays and Calculation of LC50 Doses for PARP Inhibitors
Cells were seeded into 96-well plates (UWB1.289 2000 cells/well; UWB1.289+BRCA1
1000 cells/well; PEO1 1500 cells/well; PEO4 4000 cells/well; OVCAR-3 3000 cells/well;
A2780 and A2780veliR 5000 cells/well) and treated with niraparib, olaparib, rucaparib,
talazoparib (cat. #HY-10619, cat. #HY-10619, cat. #HY-10617, cat. #HY-16106, respectively;
MedChemExpress, Monmouth Junction, NJ, USA) or veliparib (ABT-888; cat. #ALX-270-
444-M005, Sapphire Biosciences, Waterloo, NSW, Australia) for 5 days before being assessed
for cell viability using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (cat.
#G3581, Promega, Madison, USA). This assay measures cellular metabolic activity and is a
surrogate for cell viability. All results using this assay are described in the context of cell
viability. Each experiment was performed in triplicate and repeated four times, with data
reported as the mean ± SEM.
Relative lethal concentration 50 (LC50), the concentration required to bring the dose
curve halfway between the top and bottom plateau of the curve, was calculated using
GraphPad Prism 9. To address the issue that some of the drugs tested did not achieve total
loss of cell viability at high levels, data were normalised to vehicle alone (100%) and the
highest drug concentration where a plateau was observed (0%). A non-linear regression
curve was fitted to the data and LC50 concentrations extrapolated [57].
4.4. Clonogenic Cell Survival Analyses
Clonogenic cell survival assays measure the ability of a single cell to grow into a colony
post an intervention, in this case treatment with a PARP inhibitor or down-regulation of
a gene. All results using this assay are described in the context of cell survival. Cells
were seeded into 6-well plates at a density of 1000 cells/well for UWB1.289+BRCA1 and
OVCAR-3, 2000 cells/well for UWB1.289, 750 cells/well for PEO1, 1500 cells/well for
PEO4, 200 cells/well for A2780 and 180 cells/well for A2780veliR. Cells were then treated
with niraparib, olaparib, rucaparib, talazoparib or veliparib for 8–21 days. Cells were fixed
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with 100% methanol for 20 min, rinsed briefly with water and stained with 0.5% w/v crystal
violet in 25% v/v methanol for 5 min [58]. Colonies were counted using the GelCount
imager (Oxford Optronix, Abingdon, England) and plating efficiency (PE) and surviving
fraction (SF) determined [59]. A Jupyter notebook script was written in Anaconda 3 and
LC50 concentrations determined based on a published method for analysis of dose-survival
curves [60].
4.5. Statistical Analysis
IBM SPSS software version 27.0 (SPSS Australasia Pty Ltd., Chatswood, NSW, Aus-
tralia) was used for statistical analyses. All results are expressed as the mean ± SEM from
at least three independent experiments unless otherwise stated. One-sample t-tests were
used to assess the efficacy of gene down-regulation. Independent samples T tests were
used to compare plating efficiency in cell survival assays. Two-way ANOVA were used to
compare paired cell lines over dose courses for different PARPis. One-way ANOVA with
Tukey’s post hoc test was used to test for multiple comparisons between cell lines at discrete
drug dosages. For all analyses, p < 0.05 was considered statistically significant.
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